Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01501422
Other study ID # MRU CU-1/2011
Secondary ID
Status Completed
Phase Phase 3
First received November 14, 2011
Last updated December 26, 2012
Start date July 2011
Est. completion date January 2012

Study information

Verified date December 2012
Source Chulalongkorn University
Contact n/a
Is FDA regulated No
Health authority Thailand: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

1. Sex hormone including estrogen have synergistic effect to serotonin activity and decrease activity of monoamine oxidase activity so the norepinephrine is not be metabolized, these substance are important to regulate hemostasis and circadian process of sleep

2. Estrogen also regulate gamma-aminobutyric acid (GABA) secretion

- GABA substance is in order to initiate sleep and continue sleep

3. According to epidemiologic data, problem of sleep was increasing in postmenopause group compare to premenopause group (aged-match)

4. This research perform to find out the actual effect of estrogen in improving sleep quality.


Description:

1. 40-60 year-old postmenopausal women with insomnia and mild-moderate vasomotor symptom were screened and included in project

2. Block of four randomization was use to categorize participants into 2 groups

- Study group (estrogen patch)

- Control group (placebo patch)

3. Sleep quality was measured before intervention by subjective and objective sleep quality

- Subjective sleep quality (self sleep questionnaire)

- Objective sleep quality (wrist actigraphy and sleep diary):

wrist actigraph sleep test at home for 1 week

4. Intervention phase : continuous use of weekly patch for 8 weeks

- Estrogen patch in study group

- Placebo patch in control group

5. Follow up phase

- At 4 weeks of use, investigator will telephone call for follow up the participant's compliance and the side effects during patch use.

- After completed use of 7th patch, sleep quality was measured again, self sleep quality questionnaire and 1 week-wrist actigraphy and sleep diary test

6. Then the data will be analysed and open label, in nonhysterectomized postmenopausal women in study group will take the medroxyprogesterone acetate for washing out the endometrium for 2 weeks

7. The participants will be counseled, further investigate and proper treatment.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 2012
Est. primary completion date January 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria:

- Postmenopausal women 40-60 years old

- Mild to moderate vasomotor symptom

- Insomnia

- fluent read and write in Thai language

- Inform consent

Exclusion Criteria:

- Acute liver and gall bladder disease

- undiagnosed abnormal bleeding per vagina

- History of BIRADs 3 from mammogram

- History or current venous thrombosis, embolism

- diagnosis of sleep disorder

- use of hypnotic drug or antihistamine in the past month

- Diagnosis of psychiatric disorder such as depressive disorder, schizophrenia, anxiety disorder

- No past history of malignancy

- No history of chronic renal disease, alzheimer's disease, uncontrolled hypertension, uncontrolled diabetes mellitus

- history of estrogen use in past 6 months

- drug abuse, Alcohol

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Estrogen patch
50 microgram estrogen patch weekly
Placebo
Placebo patch for 8 weeks

Locations

Country Name City State
Thailand Menopause Clinic, Menopause research unit, King Chulalongkorn Memorial Hospital Pathumwan Bangkok

Sponsors (1)

Lead Sponsor Collaborator
Chulalongkorn University

Country where clinical trial is conducted

Thailand, 

References & Publications (10)

Ensrud KE, Stone KL, Blackwell TL, Sawaya GF, Tagliaferri M, Diem SJ, Grady D. Frequency and severity of hot flashes and sleep disturbance in postmenopausal women with hot flashes. Menopause. 2009 Mar-Apr;16(2):286-92. doi: 10.1097/gme.0b013e31818c0485. — View Citation

Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001;15(10):797-817. Review. — View Citation

Huang KE, Baber R; Asia Pacific Tibolone Consensus Group. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric. 2010 Aug;13(4):317-27. doi: 10.3109/13697131003681458. Review. — View Citation

Kalleinen N, Polo O, Himanen SL, Joutsen A, Polo-Kantola P. The effect of estrogen plus progestin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women. Climacteric. 2008 Jun;11(3):233-43. doi: 10.1080/13697130802112033. — View Citation

Polo-Kantola P, Erkkola R, Helenius H, Irjala K, Polo O. When does estrogen replacement therapy improve sleep quality? Am J Obstet Gynecol. 1998 May;178(5):1002-9. — View Citation

Saletu B. Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest. Climacteric. 2003 Aug;6 Suppl 2:37-45. — View Citation

Sarti CD, Chiantera A, Graziottin A, Ognisanti F, Sidoli C, Mincigrucci M, Parazzini F; Gruppo di Studio IperAOGOI. Hormone therapy and sleep quality in women around menopause. Menopause. 2005 Sep-Oct;12(5):545-51. Epub 2005 Sep 1. — View Citation

Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002 Nov;77(11):1207-18. Review. Erratum in: Mayo Clin Proc. 2004 Aug;79(8):1088. — View Citation

Tranah GJ, Parimi N, Blackwell T, Ancoli-Israel S, Ensrud KE, Cauley JA, Redline S, Lane N, Paudel ML, Hillier TA, Yaffe K, Cummings SR, Stone KL. Postmenopausal hormones and sleep quality in the elderly: a population based study. BMC Womens Health. 2010 May 4;10:15. doi: 10.1186/1472-6874-10-15. — View Citation

Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas. 1992 Mar;14(3):225-36. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Sleep efficiency (SE) Sleep efficiency is proportion of sleep in the period potentially filled by sleep-ratio of total sleep time to time in bed. 8 months Yes
Secondary Sleep latency (SL) Sleep latency is the time period measured from "lights out," or bedtime, to the beginning of sleep. 8 months Yes
Secondary Total sleep time (TST) TST is amount of actual sleep time in a sleep period. 8 months Yes
Secondary Wake time after sleep onset (WASO) WASO is the total time of awake occurring between sleep onset and final wake up. 8 months Yes
Secondary Number of awakening Number of awakening is the number of awakening during onset of sleep and final wake-up. 8 months Yes
Secondary Score of two sleep quality assessment questionnaires. Insomnia severity index is the 7 topic questionnaire for determine the severity of insomnia problem.
Ebworth severity index is the questionnaire to assess daytime sleepiness.
8 months Yes